Le Lézard
Classified in: Health
Subject: FDA

Anchora Medical Receives FDA clearance for its Su2uraŽ Minimally-Invasive Surgical Suturing Device


CAESAREA, Israel, July 1, 2021 /PRNewswire-PRWeb/ -- Anchora Medical, an Israel-based medical device company, announced today that it has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) to market its Su2uraŽ Approximation Device, an innovative, automated suturing device used in laparoscopic surgery, for the placement of interrupted or running stitches in soft tissue.

Today, standard laparoscopic suturing during Minimal-Invasive Surgery (MIS) is complex and technically challenging. Surgeons face altered depth perception, two-dimensional vision, a small working field, and use long instruments, where the needle driver is far from the surgeon's hand, making precision suturing challenging.

The Su2uraŽ Approximation Device enables a simple, automated single-trigger operation that combines simplicity, strength, and durability of sutures during MIS. By simplifying the suturing procedure, the Su2uraŽ Approximation Device aims to shorten operation time, lower costs, reduce risks and improve clinical outcomes.

The proprietary, patent protected Su2uraŽ Approximation Device incorporates tiny stainless-steel smart anchors threaded on a surgical thread to create sutures seamlessly adjusted by the surgeon for precision suturing in small spaces. It is a sterile single-use device operated through a 5 mm laparoscopic port.

The Su2uraŽ device has been used in human trials, performing laparoscopic procedures and successfully closing primary umbilical hernia defects prior to mesh fixation. The surgeries are being performed in two medical centers.

Anchora's CEO, Yoni Epstein, commented: "We are proud to receive FDA clearance for our novel Su2uraŽ Approximation Device which will set a new standard in the way laparoscopic and endoscopic suturing is performed during MIS. The FDA clearance signifies a critical milestone in our development and will enable us to move forward to commercialization."

Anchora Chairman, Dr. Shimon Eckhouse, added: "Similar to sewing machines becoming a household item, Anchora Medical was founded in 2014 to extend these same ideas to bring automated and simplified suturing to minimally invasive surgery. We are delighted the Su2uraŽ has received FDA clearance to turn this vision into a reality."

Among Anchora's investors are HOYA Corporation (ADR: HOCPY, TYO: 7741), Dr. Shimon Eckhouse, Alon Medtech Ventures, Tal Capital, and other private investors.

About Anchora Medical:
Anchora Medical is a privately-held medical device company based in Israel. Its platform technology is devoted to changing suturing in both laparoscopic and endoscopic procedures. Anchora was founded as part of the IIA, Alon Medtech incubator. For more information, visit: http://www.anchora-medical.com .

Media Contact

Viki Gronau, Joya Marketing, +972 542587278, viki@joya-marketing.com

Yoni Epstein, Anchora Medical, +972547776615, Yoni@anchora-medical.com

 

SOURCE Anchora Medical


These press releases may also interest you

at 07:45
LexaGene Holdings, Inc.,  ("LexaGene" or the "Company"), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing for veterinary diagnostics and biopharmaceutical manufacturing, today announced it has...

at 07:35
Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting and Postgraduate Course from a survey highlighting prevalence and impact of...

at 07:35
Applied DNA Sciences, Inc. (Applied DNA or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced that it has submitted its request for Emergency Use Authorization (EUA) to...

at 07:35
Xeris Biopharma Holdings, Inc. , a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck , with an...

at 07:35
Arrowhead Pharmaceuticals Inc. today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-C3, the company's investigational RNA interference (RNAi) therapeutic being developed as a treatment for...

at 07:35
Aptinyx Inc. , a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November...



News published on 1 july 2021 at 08:55 and distributed by: